{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"18.75","upperLimit":"18.75","value":"18.75"},{"groupId":"OG005","lowerLimit":"-13.98","upperLimit":"-13.98","value":"-13.98"},{"groupId":"OG006","lowerLimit":"113.71","upperLimit":"113.71","value":"113.71"},{"groupId":"OG007","lowerLimit":"-22.7","upperLimit":"45.9","value":"11.62"},{"groupId":"OG008","lowerLimit":"-88.7","upperLimit":"240.5","value":"-25.17"},{"groupId":"OG009","lowerLimit":"-46.1","upperLimit":"666.2","value":"37.85"},{"groupId":"OG010","lowerLimit":"47.1","upperLimit":"980.5","value":"180.94"},{"groupId":"OG011","lowerLimit":"-89.0","upperLimit":"1924.4","value":"73.19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"25"}],"units":"Participants"}],"description":"In the dose escalation part, CA-125 was only assessed for participants with ovarian cancer. In the dose expansion part, CA-125 was intended to be assessed only for participants with ovarian and endometrium cancer, but was additionally assessed for some participants with NSCLC and cervical cancer.","dispersionType":"Full Range","groups":[{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.","id":"OG000","title":"Dose Escalation Part: 0.3 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.","id":"OG001","title":"Dose Escalation Part: 0.6 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.","id":"OG002","title":"Dose Escalation Part: 0.9 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.","id":"OG003","title":"Dose Escalation Part: 1.2 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.","id":"OG004","title":"Dose Escalation Part: 1.5 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.","id":"OG005","title":"Dose Escalation Part: 1.8 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG006","title":"Dose Escalation Part: 2.0 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.","id":"OG007","title":"Dose Escalation Part: 2.2 mg/kg"},{"description":"Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0mg/kg of body weight.","id":"OG008","title":"Dose Expansion Part: Cervical Cancer"},{"description":"Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG009","title":"Dose Expansion Part: Endometrial Cancer"},{"description":"Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG010","title":"Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)"},{"description":"Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG011","title":"Dose Expansion Part: Ovarian Cancer"}],"paramType":"MEDIAN","populationDescription":"Analyses includes all participants in the dose escalation and expansion parts with ovarian cancer and some participants with NSCLC and cervical cancer in the dose expansion part who have a baseline and end of study evaluable assessment.","reportingStatus":"POSTED","timeFrame":"Day 1 to end of follow-up, up to a maximum of 60 weeks","title":"Dose Escalation and Expansion Part: Percentage Change From Baseline in CA-125","type":"SECONDARY","unitOfMeasure":"Percentage Change"}